Cyclosporine nephropathy: Pathophysiology and clinical impact

Seminars in Nephrology

Volumn 16, Issue 6, 1996, Pages 536-547

  Shihab, Fuad S ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; FISH OIL; NIFEDIPINE; PREDNISONE; STEROID; THROMBOXANE SYNTHASE INHIBITOR;

AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG MECHANISM; DRUG THERAPY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; ORGAN TRANSPLANTATION;

EID: 0029857451     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Kahan BD: Cyclosporine N Engl J Med 321:1725-1738, 1989
2. Cecka JM, Terasaki PI: The UNOS scientific renal transplant registry, in Terasaki PI, Cecka JM (eds): Clinical Transplants 1994 Los Angeles, CA, UCLA Tissue Typing Laboratory, 1994, pp 1-18
3. Myers BD: Cyclosporine nephrotoxicity Kidney Int 30:964-974, 1988
4. Bennett \VM: The nephrotoxicity of immunosuppressive drugs Clin Nephrol 43:S3-S7, 1995
5. Kopp JB, Klotman PE: Cellular and molecular mechanisms of cyclosporine nephrotoxicity J Am Soc Nephrol 1:162-179, 1990
6. Wolfe JA, McCann RL, Sanfilippo F: Cyclosporine-associated microangiopathy in renal transplantation Transplantation 41:541-544, 1986
7. Liu J, Farmer JD Jr, Lane WS, et al: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes Cell 66:807-815, 1991
8. Schreiber SL: Immunophilin-sensitive protein phosphatase action in cell signaling pathways Cell 70:365-368, 1992
9. Morris PJ: Cyclosporine, in Morris PJ (ed): Kidney Transplantation: Principles and Practice 4th ed Philadelphia, PA, Saunders, 1994, pp 179-201
10. Mueller EA, Kovarik JM, Van Bree JB, et al: Pharmacokinetics and tolerability of a microemulsion formulation in renal allograft recipients Transplantation 57:1178-1182, 1994
11. Remuzzi G, Perico N: Cyclosporine-induced renal dysfunction in experimental animals and humans Kidney Int 48:S70-S74, 1995 (suppl 52)
12. Novick AC, Ho-Hsieh H, Steinmuller DS, et al: Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation: Results of randomized prospective trial Transplantation 42:154-158, 1986
13. Ruggenenti P, Perico N, Mosconi L, et al: Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion Kidney Int 43:706-711, 1993
14. Perico N, Ruggenenti P, Gaspari F, et al: Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantTransplantation 54:56-60, 1992
15. Curtis JJ, Luke RG, Dubovsky E, et al: Cyclosporin in therapeutic doses increases renal allograft vascular resistance Lancet 2:477-479, 1986
16. Mihatsch MJ, Ryffel B, Gudat F: The differential diagnosis between rejection and cyclosporine toxicity Kidney Int 48:S63-S69, 1995 (suppl 52)
17. Myers BD, Ross JC, Newton LD, et al: Cyclosporine-associated chronic nephropathy N Engl J Med 311:699-705, 1984
18. Myers BD, Newton L, Boshkos C, et al: Chronic injury of human renal microvessels with low-dose cyclosporine therapy Transplantation 46:694-703, 1988
19. Bennett WM, Porter GA: Cyclosporine-associated hypertension Am J Med 85:131-133, 1988
20. Bellet M, Cabrol C, Sassano P, et al: Systemic hypertension after cardiac transplant: Effect of cyclosporine on the renin-angiotensin-aldosterone system Am J Cardiol 56:927-931, 1985
21. Curtis JJ, Luke RG, Jones D, et al: Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent Am J Med 85:134-138, 1988
22. Roullet JB, Xue H, McCarron DA, et al: Vascular mechanisms of cyclosporine-induced hypertension in the rat J Clin Invest 93:2244-2250, 1994
23. Van Buren D, Van Buren CT, Flechner SM, et al: De novo hemolytic uremie syndrome in renal transplant patients immunosuppressed with cyclosporine Surgery 98:54-62, 1985
24. Sommer BG, Innes JT, Whitehurst RM, et al: Cyclosporine-associated renal arteriopathy resulting in loss of allograft function Am J Surg 149:756-764, 1985
25. Kamel KS, Ethier JH, Quaggin S, et al: Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine J Am Soc Nephrol 2:1279-1284, 1991
26. +-ATPase activity by cyclosporine A Kidney Int 43:246-251, 1993
27. Stahl RA, Kanz L, Maier B, et al: Hyperchloremic metabolic acidosis with high serum potassium in renal transplant recipients: A cyclosporine A associated side effect Clin Nephrol 25:245-248, 1986
28. Lin HV, Rocher LL, McQuillan MA, et al: Cyclosporine-induced hyperuricemia and gout N Engl J Med 321:287-292, 1989
29. Barton CH, Vaziri ND, Martin DC, et al: Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine Am J Med 83:693-699, 1987
30. Lewis RM: Long term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation Kidney Int 48:S75-S78, 1995
31. Burke JFJ, Pirsch JD, Ramos EL, et al: Long term efficacy and safety of cyclosporine in renal transplant recipients N Engl J Med 331:358-363, 1994
32. 32: Slomowitz LA, Wilkerson A, Hawkins R, et al: Evaluation of kidney function in renal transplant recipients treated with cyclosporine Am J Kidney Dis 15:530-534, 1990
33. Ruiz P, Kolbeck PC, Scroggs MW, et al: Associations between cyclosporine therapy and interstitial fibrosis in renal allograft biopsies Transplantation 45:91-95, 1988
34. Klintmalm G, Sundelin B, Bohman SO, et al: Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: Beneficial effect of low doses in early post-transplant period Lancet 2:950-954, 1984
35. Mihatsch MJ, Steiner K, Abeywickrama KH, et al: Risk factors for development of chronic cyclosporine nephrotoxicity Clin Nephrol 29:165-175, 1988
36. Morozumi K, Thiel G, Albert FYV, et al: Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in renal allografts Clin Nephrol 38:1-8, 1992
37. Myers BD, Sibley R, Newton L, et al: The long term course of cyclosporine-associated chronic nephropathy Kidney Int 33:590-600, 1988
38. Greenberg A, Thompson ME, Griffith BJ, et al: Cyclosporine nephrotoxicity in cardiac allograft patients - A 7 year follow-up Transplantation 50:589-593, 1990
39. Lloveras JJ, Durand D, Adler JL, et al: Evolution of glomerular filtration rate and renal plasma flow in cyclosporine-treated heart transplant recipients Transplant Proc 25:2226, 1993
40. Zietse R, Balk AH, vd Dorpel MA: Time course of the decline in renal function in cyclosporine-treated heart transplant recipients Am J Nephrol 14:1-5, 1994
41. Bertani T, Ferrazzi P, Schieppati A, et al: Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients Kidney Int 40:243-250, 1991
42. Zaltzman JS, Pei Y, Maurer J, et al: Cyclosporine nephrotoxicity in lung transplant recipients Transplantation 54:875-878, 1992
43. Pattison JM, Petersen J, Kuo P, et al: The incidence of renal failure in one hundred consecutive heart-lung transplant patients Am J Kidney Dis 26:643-648, 1995
44. O'Grady JG, Forbes A, Rolles K, et al: An analysis of cyclosporine efficacy and toxicity after liver transplantation Transplantation 45:575-579, 1988
45. Gonwa TA, Morris CA, Goldstein RM, et al: Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndromeExperience in 300 patients Transplantation 51:428-430, 1991
46. Wheatley HC, Dantzman M, Williams JW, et al: Long-term effects of cyclosporine on renal function in liver transplant recipients Transplantation 43:641-647, 1987
47. Dische FE, Neuberger J, Keating J, et al: Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A Lab Invest 58:395-402, 1988
48. Dieterle A, Gratwohl A, Nizze H, et al: Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients Transplantation 49:1093-1100, 1990
49. Nizze H, Mihatsch MJ, Zollinger HU, et al: Cyclosporine-associated nephropathy in patients with heart and bone marrow transplants Clin Nephrol 30:248-260, 1988
50. Palestine AG, Austin HAI, Balow JE, et al: Renal histopathologic alterations in patients treated with cyclosporine for uveitis N Engl J Med 314:1293-1298, 1986
51. Austin HAI, Palestine AG, Sabnis SG, et al: Evolution of cyclosporin nephrotoxicity in patients treated for autoimmune uveitis Am J Nephrol 9:392-402, 1989
52. Deray G, Benhmida M, LeHoang P, et al: Renal function and blood pressure in patients receiving long-term, low dose cyclosporine therapy for idiopathic autoimmune uveitis Ann Intern Med 117:578-583, 1992
53. Andersen CB, Larsen S, Elmgreen J, et al: Cyclosporine-induced renal morphologie and immunohistologic changes in patients with chronic uveitis APMIS 99:576-582, 1991
54. Feutren G, Mihatsch MJ: Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases N Engl J Med 326:1654-1660, 1992
55. Assan R, Timsit J, Feutren G, et al: The kidney in cyclosporine A-treated diabetic patients: A long-term clinicopathologic study Clin Nephrol 41:41-49, 1994
56. Fioretto P, Steffes MW, Mihatsch MJ, et al: Cyclosporine-associated lesions in native kidneys of diabetic pancreas transplant patients Kidney Int 48:489-495, 1995
57. Pei Y, Scholey JW, Katz A, et al: Chronic nephrotoxicity in psoriatic patients treated with low dose cyclosporine Am J Kidney Dis 23:528-536, 1994
58. Young EW, Ellis CN, Messana JM, et al: A prospective study of renal structure and function in psoriasis patients treated with cyclosporine Kidney Int 46:1216-1222, 1994
59. Hulton SA, Jadresic L, Shah V, et al: Effect of cyclosporine A on glomerular filtration rate in children with minimal change nephrotic syndrome Pediatr Nephrol 8:404-407, 1994
60. Niaudet P, Habib R: Cyclosporine in the treatment of idiopathic nephrosis J Am Soc Nephrol 5:1049-1056, 1994
61. Meyrier A, Noel LH, Auriche P, et al: Long term renal tolerance of cyclosporine A treatment in adult idiopathic nephrotic syndrome Kidney Int 45:1446-1456, 1994
62. English J, Evan A, Houghton DC, et al: Cyclosporineinduced acute renal dysfunction in the rat Evidence of preservation of tubular function Transplantation 44:135-141, 1987
63. Rossi NF, Churchill PC, McDonald FD, et al: Mechanism of cyclosporin A-induced renal vasoconstriction in the rat J Pharmacol Exp Ther 250:896-901, 1989
64. Bobadilla NA, Tapia E, Franco M, et al: Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity Kidney Int 46:773-779, 1994
65. Scherrer U, Vissing SF, Morgan BJ, et al: Cyclosporine-induced sympathetic activation and hypertension after heart transplantation N Engl J Med 323:693-699, 1990
66. Auch-Schwelk W, Duske E, Hink U, et al: Vasomotor responses in cyclosporin A treated rats after chronic angiotensin blockade Hypertension 23:832-837, 1994
67. Stahl RAK, Adler S, Baker PJ, et ai: Cyclosporin A inhibits prostaglandin E2 formation by rat mesangial cells in culture Kidney Int 35:1161-1167, 1989
68. Erma A, Chen-Gal B, Rosenfield J, et al: The role of eicosanoids in cyclosporine nephrotoxicity in the rat Biochem Pharmacol 38:2153-2157, 1989
69. Bunchman TE, Brookshire CA: Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells J Clin Invest 88:310-314, 1991
70. Lanese DM, Conger JD: Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles J Clin Invest 91:2144-2149, 1993
71. Grieff M, Loertscher R, Shoharb SA, et al: Cyclosporine-induced elevation in circulating endothelin-1 in patients with solid organ transplantation Transplantation 56:880-884, 1993
72. Hunley TE, Fogo S, Iwasaki S, et al: Endothelin A receptor mediates functional but not structural damage in chronic cyclosporine nephrotoxicityJ Am Soc Nephrol 5:1718-1723, 1995
73. Truong LD, Farhood A, Tasby J, et al: Experimental chronic renal ischemia: Morphologic and immunologie studies Kidney Int 41:1676-1689, 1992
74. Elzinga LW, Rosen S, Bennett WM: Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: Role of sodium intake J Am Soc Nephrol 4:214-221, 1993
75. Wolf G, Killen PD, Neilson EG: Cyclosporine A stimulates transcription and procollagen secretion in tubulointerstitial fibroblasts and proximal tubular cells J Am Soc Nephrol 1:918-922, 1990
76. Ghiggeri GM, Altieri P, Oleggini R, et al: Cyclosporine enhances the synthesis of selected extracellular matrix proteins by renal cells "in culture" Transplantation 57:1382-1388, 1994
77. Nast CC, Adler SG, Artishevsky A, et al: Cyclosporine induces elevated procollagen al (I) mRNA levels in the rat renal cortex Kidney Int 39:631-638, 1991
78. Shihab FS, Andoh TF, Tanner AM, et al: Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy Kidney Int 49:1141-1151, 1996
79. Young BA, Burdmann EA, Johnson RJ, et al: Cellular proliferation and macrophage influx precedes interstitial fibrosis in cyclosporine nephrotoxicity Kidney Int 48:439-448, 1995
80. Shehata M, El-Nahas M, Barkworth E, et al: Increased platelet-derived growth factor in the kidneys of cyclosporin-treated rats Kidney Int 46:726-732, 1994
81. Khanna A, Li B, Stenzel KH, et al: Regulation of new DNA synthesis in mammalian cells by cyclosporine Transplantation 57:577-582, 1994
82. Shehata M, Cope GH, Johnson TS, et al: Cyclosporine enhances the expression of TGF-β in juxtaglomerular cells of the rat kidney Kidney Int 48:1487-1496, 1995
83. Ahuja SS, Shrivastav S, Danielpour D, et al: Regulation of transforming growth factor-β1 and its receptor by cyclosporine in human T lymphocytes Transplantation 60:718-723, 1995
84. Border WA, Noble NA: Transforming growth factor in tissue fibrosis N Engl J Med 331:1286-1292, 1994
85. Kurihara H, Yoshizumi M, Sugiyama T, et al: TGF-β stimulates the expression of endothelin mRNA by vascular endothelial cells Biochem Biophys Res Commun 159:1435, 1989
86. Ruscetti FW, Palladino MA: Transforming growth factor-β and the immune system Prog Growth Factor Res 3:159-175, 1991
87. Khanna A, Li B, Sehajpal PK, et al: Mechanism of action of cyclosporine: A new hypothesis implicating transforming growth factor-β Transplant Rev 9:41-48, 1995
88. Mason J, Müller-Schweinitzer E, Supont M, et al: Cyclosporine and the renin-angiotensin system Kidney Int 39:S28-S32, 1991
89. Meister B, Lippoldt A, Bunnemann B, et al: Cellular expression of angiotensin type-1 receptor mRNA in the kidney Kidney Int 44:331-336, 1993
90. Johnson RJ, Alpers CE, Yoshimura A, et al: Renal injury from angiotensin II-mediated hypertension Hypertension 19:464-474, 1992
91. Keane WF, Anderson S, Aurell M, et al: Angiotensin converting enzyme inhibitors and progressive renal insufficiencyAnn Intern Med 111:503-516, 1989
92. Kagami S, Border WA, Miller DE, et al: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells J Clin Invest 93:2431-2437, 1994
93. Wolf G, Ziyadeh FN, Zahner G, et al: Angiotensin II-stimulated expression of transforming growth factor beta in renal proximal tubular cells: Attenuation after stable transfection with the c-mas oncogene Kidney Int 48:1818-1827,1995
94. Shihab FS, Andoh TF, Tanner AM, et al: Angiotensin II mediates fibrosis and modulates TGF-β1 expression in experimental chronic cyclosporine nephrotoxicity 15th Annual Meeting of the American Society of Transplant Physicians, Dallas, TX, 1996
95. Friedman J, Weissman I: Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin Cell 66:799-806, 1991
96. Palmer BF, Dawidson I, Sagalowsky I, et al: Improved outcome of cadaveric renal transplant due to calcium channel blockersTransplantation 52-640-645, 1991
97. Chrysostomou A, Walker RG, Russ GR, et al: Diltiazem in renal allograft recipients receiving cyclosporine Transplantation 55:300-304, 1993
98. McCulloch TA, Harper SJ, Donnelly PK, et al: Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A J Clin Pathol 47:839-842, 1994
99. Mourad G, Ribstein J, Mimran A: Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants Kidney Int 43:419-425, 1993
100. Homan vd Heide JJ, Bilo HJG, Donker JM, et al: Effect of dietary fish oil on renal function and rejection in CsA-treated recipients of renal transplants N Engl J Med 329:769-773, 1993
101. Smith SR, Kubacki VB, Rakhit A, et al: Chronic thromboxane synthesis inhibition with COS 12970 in human cyclosporine nephrotoxicity Transplantation 56:1422-1426, 1993